Tadalafil is sufficiently effective for severe chronic prostatitis/chronic pelvic pain syndrome in patients with benign prostatic hyperplasia

Objectives To investigate the efficacy of tadalafil for patients with benign prostatic hyperplasia and chronic prostatitis/chronic pelvic pain syndrome. Methods Tadalafil 5 mg was given each morning for 12 weeks to patients diagnosed as having either moderate or severe lower urinary tract symptoms....

Full description

Saved in:

Bibliographic Details
Published in:	International journal of urology Vol. 27; no. 1; pp. 53 - 57
Main Authors:	Hiramatsu, Ippei, Tsujimura, Akira, Soejima, Miho, Yoshiyama, Azusa, Nagashima, Yuki, Ishikawa, Keisuke, Uesaka, Yuka, Nozaki, Taiji, Ogishima, Tatsuya, Shirai, Masato, Mitsuhashi, Isao, Sugimura, Sosuke, Mizuno, Taiki, Noto, Kensho, Shigeta, Yasuhiro, Takasu, Jiro, Honda, Shinichi, Iwata, Shinji, Horie, Shigeo
Format:	Journal Article
Language:	English
Published:	Australia Wiley Subscription Services, Inc 01-01-2020
Subjects:	Adult Aged Aged, 80 and over Benign benign prostatic hyperplasia Chronic pain chronic prostatitis/chronic pelvic pain syndrome Humans Hyperplasia lower urinary tract symptom Male Middle Aged National Institutes of Health Chronic Prostatitis Symptom Index Pain Phosphodiesterase 5 Inhibitors - therapeutic use Prostate Prostatic Hyperplasia - complications Prostatic Hyperplasia - drug therapy Prostatitis Prostatitis - complications Prostatitis - drug therapy Retrospective Studies Severity of Illness Index tadalafil Tadalafil - therapeutic use Urinary tract lower urinary tract symptom National Institutes of Health Chronic Prostatitis Symptom Index tadalafil benign prostatic hyperplasia chronic prostatitis/chronic pelvic pain syndrome
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Objectives To investigate the efficacy of tadalafil for patients with benign prostatic hyperplasia and chronic prostatitis/chronic pelvic pain syndrome. Methods Tadalafil 5 mg was given each morning for 12 weeks to patients diagnosed as having either moderate or severe lower urinary tract symptoms. Voiding symptoms were compared between patients with a high (≥4; high group) and low (<4; low group) pain subscore of the National Institutes of Health Chronic Prostatitis Symptom Index before and after tadalafil administration. The correlation between changes in the Chronic Prostatitis Symptom Index and the International Prostate Symptom Score during treatment was also investigated. Results At baseline, the pain subscore of the Chronic Prostatitis Symptom Index was high (≥4) in 24 of 74 (32.4%) patients. The International Prostate Symptom Score in the group with a high pain subscore was significantly higher than that in the group with a low pain subscore. International Prostate Symptom Score, National Institutes of Health Chronic Prostatitis Symptom Index total score and pain subscore were all significantly improved after treatment. The change in the Chronic Prostatitis Symptom Index total score correlated positively with the change in the International Prostate Symptom Score. The decrease in the International Prostate Symptom Score was significantly greater in the group with high versus low pain subscore. Conclusions Tadalafil is sufficiently effective in the treatment of patients with benign prostatic hyperplasia and severe chronic prostatitis/chronic pelvic pain syndrome.
ISSN:	0919-8172 1442-2042
DOI:	10.1111/iju.14122